Your session is about to expire
← Back to Search
Open-label Maintenance Phase: Guselkumab SC for Ulcerative Colitis (QUASAR Jr Trial)
QUASAR Jr Trial Summary
"This trial aims to see how well guselkumab works in children with moderate to severe ulcerative colitis after they have already responded well to the initial treatment."
QUASAR Jr Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowQUASAR Jr Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.QUASAR Jr Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What criteria must individuals meet to participate in this medical study?
"Patients aged between 2 and 17 years old diagnosed with ulcerative colitis are sought to participate in this study, which aims to recruit a total of 120 individuals."
Can individuals who are above the age of 55 participate in this research study?
"Eligible candidates for this study must fall within the age bracket of 2 to 17 years. There are a total of 65 trials catering to individuals under 18 and 314 studies targeting those over the age of 65."
Are there any ongoing efforts to enroll participants in this medical study at the moment?
"As per clinicaltrials.gov, this investigation is actively pursuing candidates. The trial was first made public on January 19th, 2024 and its latest update was on February 7th, 2024."
What is the overall count of participants involved in this clinical investigation?
"Affirmative. The details on clinicaltrials.gov indicate an ongoing recruitment phase for this study, which was first listed on January 19th, 2024 and last revised on February 7th, 2024. A total of 120 individuals are sought across two designated sites."
What are the safety considerations for patients receiving guselkumab intravenously during the open-label induction phase?
"According to our team at Power, the safety rating for the Open-label Induction Phase: Guselkumab Intravenously (IV) trial is a 3. This is due to its Phase 3 status, indicating existing efficacy data and numerous rounds of safety data."
Share this study with friends
Copy Link
Messenger